|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 18.52 0.0002 0.0011%
Dr. Geoffrey McDonough, M.D. no longer serves as President and Chief Executive Officer of Swedish Orphan Biovitrum AB effective as of July 1, 2017. He has held the position since August 15, 2011. He is also Board member of Zafgen and PTC Therapeutics. He previously served for Genzyme Corporationrationration in the United States from 2002, where he has over the years held such roles as Senior Vice President and General Manager, Personalized Genetic Health Senior Vice President, Global Business Unit Leader, LSD Therapeutics, and most recently, President of Europe, Middle East, and Africa . Prior to joining Genzyme, he worked as a pediatrician in the United States, and was also President, and Cofounder of Catalyst Medical Solutions Inc. He graduated from Harvard Medical School with a Medical Doctor degree. He holds a Bachelor of Arts in Philosophy and a BS in Biology degrees from the University of North Carolina.
Age: 44 CEO Since 2011 Ph.D
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 9.59 %
which means that it generated profit of $9.59 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 19.06 %
meaning that it generated $19.06 on every $100 dollars invested by stockholders.
The company has accumulated 833.91 K in total debt with debt to equity ratio (D/E) of 0.1 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.72 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 800 people.
Swedish Orphan Biovi Leadership Team
|Hans Wigzell, Director, Ph.D|
|Lennart Johansson, Director, MBA|
|Annette Clancy, Director|
|Trista Morrison, President|
|Kirsti Gjellan, President|
|Jorgen Winroth, VP|
|Milan Zdravkovic, President, Ph.D|
|Hans Schikan, Director|
|Dennis Pedersen, President|
|Helena Saxon, Director, MBA|
|Anders Edvell, Executive, MBA|
|Geoffrey McDonough, CEO, Ph.D|
|Lars Dreioee, President, MBA|
|Alan Raffensperger, COO|
|Fredrik Berg, Executive|
|BoGunnar Rosenbrand, Director|
|Adine Axen, Director|
|Birgitte Volck, President|
|MatsOlof Wallin, President|
|Stefan Fraenkel, President, MBA|
|Hakan Bjorklund, Chairman, Ph.D|
|Cecilia Forberg, President|
|Stephen James, President, Ph.D|
|Bo Hansen, Chairman, Ph.D|
|Armin Reininger, President, Ph.D|
|Catarina Larsson, Director|
|Wills HughesWilson, President|
|Guido Oelkers, CEO|
|Jeffrey Jonas, Director, Ph.D|
|Matthew Gantz, Director, MBA|
|Theresa Heggie, Director|
Stock Performance Indicators
Macroaxis portfolio users are unresponsive in their opinion about investing in Swedish Orphan Biovitrum AB. What is your outlook on investing in Swedish Orphan Biovitrum AB? Are you bullish or bearish?
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1)
For any level of risk, select the one which has the highest expected return. 2)
For any expected return, select the one which has the lowest volatility.